NLRP3 and neoplasm: Concurrently, the inhibition of the NLRP3 inflammasome mitigates IL—1β—driven immunosuppression within the tumor microenvironment, while PD—1 blockade further promotes CD8+ T—cell infiltration by surmounting T—cell checkpoint inhibition.